Tango Therapeutics TNGX Stock
Tango Therapeutics Price Chart
Tango Therapeutics TNGX Financial and Trading Overview
| Tango Therapeutics stock price | 1.28 USD |
| Previous Close | 3.51 USD |
| Open | 3.5 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 900 |
| Day's Range | 3.36 - 3.66 USD |
| 52 Week Range | 2.47 - 8.56 USD |
| Volume | 81.72K USD |
| Avg. Volume | 224.64K USD |
| Market Cap | 319.15M USD |
| Beta (5Y Monthly) | 1.63773 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.19 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.2 USD |
TNGX Valuation Measures
| Enterprise Value | 18.04M USD |
| Trailing P/E | N/A |
| Forward P/E | -2.375 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 12.83366 |
| Price/Book (mrq) | 1.4013975 |
| Enterprise Value/Revenue | 0.725 |
| Enterprise Value/EBITDA | -0.158 |
Trading Information
Tango Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.63773 |
| 52-Week Change | -23.67% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 8.56 USD |
| 52 Week Low | 2.47 USD |
| 50-Day Moving Average | 3.6 USD |
| 200-Day Moving Average | 5.38 USD |
TNGX Share Statistics
| Avg. Volume (3 month) | 224.64K USD |
| Avg. Daily Volume (10-Days) | 402.21K USD |
| Shares Outstanding | 88.41M |
| Float | 43.74M |
| Short Ratio | 9.82 |
| % Held by Insiders | 15.32% |
| % Held by Institutions | 78.30% |
| Shares Short | 1.84M |
| Short % of Float | 4.19% |
| Short % of Shares Outstanding | 2.08% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -466.37% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -16.56% |
| Return on Equity (ttm) | -40.53% |
Income Statement
| Revenue (ttm) | 24.87M USD |
| Revenue Per Share (ttm) | 0.28 USD |
| Quarterly Revenue Growth (yoy) | 0.10% |
| Gross Profit (ttm) | -81046000 USD |
| EBITDA | -114098000 USD |
| Net Income Avi to Common (ttm) | -110976000 USD |
| Diluted EPS (ttm) | -1.22 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 333.64M USD |
| Total Cash Per Share (mrq) | 3.77 USD |
| Total Debt (mrq) | 41.37M USD |
| Total Debt/Equity (mrq) | 18.21 USD |
| Current Ratio (mrq) | 6.391 |
| Book Value Per Share (mrq) | 2.576 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -114322000 USD |
| Levered Free Cash Flow (ttm) | -47807248 USD |
Profile of Tango Therapeutics
| Country | United States |
| State | MA |
| City | Boston |
| Address | 201 Brookline Avenue |
| ZIP | 02215 |
| Phone | 857 320-4900 |
| Website | https://www.tangotx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 110 |
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Q&A For Tango Therapeutics Stock
What is a current TNGX stock price?
Tango Therapeutics TNGX stock price today per share is 1.28 USD.
How to purchase Tango Therapeutics stock?
You can buy TNGX shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Tango Therapeutics?
The stock symbol or ticker of Tango Therapeutics is TNGX.
Which industry does the Tango Therapeutics company belong to?
The Tango Therapeutics industry is Biotechnology.
How many shares does Tango Therapeutics have in circulation?
The max supply of Tango Therapeutics shares is 108.11M.
What is Tango Therapeutics Price to Earnings Ratio (PE Ratio)?
Tango Therapeutics PE Ratio is now.
What was Tango Therapeutics earnings per share over the trailing 12 months (TTM)?
Tango Therapeutics EPS is -1.19 USD over the trailing 12 months.
Which sector does the Tango Therapeutics company belong to?
The Tango Therapeutics sector is Healthcare.
Tango Therapeutics TNGX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17449.89 USD — |
+0.87
|
6.97B USD — | 17149.36 USD — | 17506.58 USD — | — - | 6.97B USD — |
| NASDAQ Global Market Composite NQGM | 1814.37 USD — |
-0.65
|
— — | 1794.87 USD — | 1837.48 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4132.89 USD — |
-2.63
|
— — | 4122.19 USD — | 4247.3 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 929.13 USD — |
-1.85
|
— — | 925.14 USD — | 947.12 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4486.38 USD — |
-0.37
|
— — | 4281.91 USD — | 4648.11 USD — | — - | — — |
- {{ link.label }} {{link}}